The White House declared this week Overdose Awareness Week, boasting $22 billion of new investment to address the overdose crisis – including massive investments in “expanding access to life-saving medications.”

Telehealth treatment for opioid addiction is working. Pandemic flexibilities helped Americans access life-saving medications like buprenorphine without increasing misuse. So why are we going backward? The DEA’s newly proposed “guardrails” are more aptly “roadblocks” for addiction patients and providers alike.

The DEA announced a proposal for new rules for prescribing controlled substances - including buprenorphine - that could impact telehealth patients and add a single in-person requirement. Boulder is prepared to help patients navigate this change and fight back to make treatment easy and accessible.

The COVID-era PHE made SUD care accessible in a profound new way. But that could all change once the PHE expires. Boulder has been preparing to ensure continuity of care for our current and future patients and is actively advocating for better regulations to help all people in need of addiction care.

Dave Lerman, Boulder's CTO, details how a personal experience helped him see a need for more support and funding for studies into the potential of psychedelics.

Ben MacLean, Boulder's General Counsel, explains how laws and regulations can fight against patients with SUDs and stand in the way of better treatment options.

Alyson Smith, Boulder Care’s Medical Director, shares how rewarding working with SUD patients has been for her and how urgent the need is for more clinicians to do the same.